Acquisition - August 18, 2026
LEO Pharma acquires dersimelagon rights from Tanabe
LEO Pharma is acquiring worldwide rights to dersimelagon from Japan’s Tanabe Pharma in a deal worth up to USD 435 million, strengthening the Danish company’s rare dermatology pipeline.
New Market - August 18, 2026
NextCell selected as the only Swedish company in the EU-Japan Biotech Business Mission 2026
In parallel, the company is strengthening its local presence in Hong Kong by establishing an office and becoming a member of the Hong Kong-Shenzhen Innovation and Technology Park (HSITP).
Financing - August 14, 2026
AlzeCure receives upfront payment of USD 12 million and completes initial transaction with QuantumCell
AlzeCure Pharma has now received the full upfront payment of USD 12 million from the Danish biotech company QuantumCell.
Agreement - August 13, 2026
Zealand Pharma enters into royalty purchase and sale agreement with Royalty Pharma
Zealand Pharma has entered into a royalty purchase and sale agreement with Royalty Pharma in exchange for Zealand Pharma’s economics related to rusfertide (PTG-300), a potential first-in-class therapy for polycythemia vera, a rare and chronic blood disorder.
Collaboration - August 11, 2026
Novo Nordisk and AWS enter strategic partnership
Novo Nordisk and Amazon Web Services (AWS) have announced a strategic partnership to accelerate drug discovery and modernise Novo Nordisk’s operations through agentic AI and cloud technologies.
Pharma Business - August 11, 2026
Bavarian Nordic receives European Commission approval of Mpox/Smallpox Vaccine
The European Commission has adopted the recent Committee for Medicinal Products for Human Use (CHMP) positive opinion recommending the approval of a type II variation for IMVANEX (MVA-BN) smallpox and mpox vaccine, extending the current marketing authorization to include children 2 to less than 12 years of age.
